Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Current and Projected Market Size of the HER2-Negative Breast Cancer Market Through 2034?
The market size for HER2-negative breast cancer has witnessed significant growth over the past few years. It is projected to rise from $16.29 billion in 2024 to $17.62 billion in 2025, registering a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this surge during the historic period include a rise in breast cancer incidences, a greater understanding of breast cancer, heightened healthcare expenditure, an increasing aging population, and growth in healthcare facilities.
There is an expectation of significant expansion in the market size for HER2-negative breast cancer in the upcoming years. By 2029, the market is projected to reach $23.86 billion, with a compound annual growth rate (CAGR) of 7.9%. This predicted surge in the forecast period can be credited to factors such as rising levels of alcohol and tobacco use, escalation in adoption of detrimental lifestyle habits, augmented incidence of obesity, and a mounting need for efficient treatment methodologies. The forecast period is also likely to witness major trends such as advancements in diagnostic technologies, the introduction of target-specific therapies, the incorporation of immunotherapies, FDA validations, and breakthroughs in technology.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the HER2-Negative Breast Cancer Market?
The surge in incidences of breast cancer is projected to fuel the expansion of the HER2-negative breast cancer market. Breast cancer, typified by erratic growth of abnormal cells in the breast tissue, often originating from the ducts or lobules, is becoming more prevalent. The escalation in breast cancer cases is attributable to several aspects, including heightened awareness and advancements in screening methods, resulting in more common and earlier detection. The vital role that HER2-negative breast cancer plays in expediting breast cancer research through insights into diverse tumor biology and treatment approaches significantly aids the development of more personalized therapies for patients. For instance, data from the Centers for Disease Control and Prevention, a US-based public agency, indicated that there were 272,454 newly diagnosed breast cancer cases among females in 2021 and 42,211 female deaths in 2022 in the United States. Consequently, the surge in breast cancer incidence serves as the drive behind the growth of the HER2-negative breast cancer market.
Which Segments in the HER2-Negative Breast Cancer Offer the Most Growth?
The HER2-negative breast cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy
2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites
2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)
3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors
4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21203&type=smp
What Are the Fastest-Growing Geographies in the How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the HER2-Negative Breast Cancer Market? Market?
North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Current Market Growth and Trends in the HER2-Negative Breast Cancer Industry?
Major firms active in the HER2-negative breast cancer market are striving to secure regulatory consent to launch fresh treatment methods, broaden their product lines, and increase their market visibility. Regulatory consent is the formal permission given by government bodies that enables firms to sell and distribute medications or treatments after they have satisfied safety, efficacy, and quality criteria. For instance, in October 2024, Genentech Inc., a biotechnology firm based in the United States, secured FDA clearance for Itovebi (inavolisib), aimed at treating advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This permission permits the use of Itovebi together with palbociclib and fulvestrant, markedly enhancing the progression-free survival of patients in contrast to traditional treatments. This novel regimen offers a crucial alternative for patients with limited therapy options, underlining the significance of biomarker testing in determining those who would reap the greatest benefit from this treatment.
View the full report here:
https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report
What Are the Key Elements That Define the HER2-Negative Breast Cancer Market?
HER2-negative breast cancer refers to a type of breast cancer where the cancer cells do not have high levels of the HER2 protein, which promotes tumour growth. This type of cancer tends to grow more slowly than HER2-positive breast cancer and is treated with targeted therapies and chemotherapy.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21203
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model